Content about HIV treatment

December 27, 2012
Managing HIV/AIDS treatment

The Obama administration recently stressed the importance of increasing coverage of HIV treatment, as well as increasing access to HIV testing and counseling. It's an initiative that Walgreens, with more than 700 HIV-specialized pharmacies and over 2,000 pharmacists with special HIV/AIDS-accredited educational training, follows closely. Walgreens' senior manager for HIV/AIDS and hepatitis pharmacy services Glen Pietrandoni talked with DSN on the scope of Walgreens' HIV/AIDS services.

AUDIO Q&A: Walgreens' senior manager for HIV/AIDS and hepatitis pharmacy services Glen Pietrandoni talked with DSN on the scope of Walgreens' HIV/AIDS services.The Obama administration recently stressed the importance of increasing coverage of HIV treatment, as well as increasing access to HIV testing and counseling.

January 15, 2013
Switching to multi-pill generic HIV treatment could diminish effectiveness, study finds

While replacing a single combination pill for HIV with generics would save the healthcare system money, it could also diminish the effectiveness of treatment, a new study suggests.

NEW YORK — While replacing a single combination pill for HIV with generics would save the healthcare system money, it could also diminish the effectiveness of treatment, a new study suggests.

The study, led by investigators at the Massachusetts General Hospital and Weill Cornell Medical College, and published in the Jan. 15 issue of Annals of Internal Medicine, found $1 billion in potential savings, but the more complicated treatment regimen might result in more patients missing doses and a loss of drug effectiveness.

August 28, 2012
FDA approves new combination pill for HIV treatment for some patients

The Food and Drug Administration has approved a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.

FOSTER CITY, Calif. — The Food and Drug Administration has approved a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.

May 26, 2011
Teva to market generic Combivir tablets

Teva Pharmaceutical Industries is set to market a generic version of an HIV treatment, the drug maker announced Thursday.

JERUSALEM — Teva Pharmaceutical Industries is set to market a generic version of an HIV treatment, the drug maker announced Thursday.

Teva said it will launch generic Combivir tablets (lamivudine and zidovudine) and is eligible for a 180-day period of marketing exclusivity, according to the Food and Drug Administration. The drug maker is expected to ship the drug in fourth quarter 2011, per terms of a settlement agreement between Teva, Glaxo Group and ViiV Healthcare.

January 27, 2011
Matrix obtains license agreement for HIV treatment

A Mylan subsidiary has inked a nonexclusive license agreement with Tibotec Pharmaceuticals to manufacture, market and distribute a generic version of an HIV treatment.

PITTSBURGH — A Mylan subsidiary has inked a nonexclusive license agreement with Tibotec Pharmaceuticals to manufacture, market and distribute a generic version of an HIV treatment.

Pending the regulatory approval of TMC278 (rilpivirine hydrochloride), Matrix Labs will have the right to manufacture once-daily 25-mg TMC278 as a single-agent medicine and a fixed-dose combination product, Mylan said. Matrix also will be able to market the drug in sub-Saharan Africa, certain developing countries and India.

December 21, 2010
In pact with Oncolys, Bristol-Myers Squibb snags rights to investigational HIV compound

Bristol-Myers Squibb has signed a definitive licensing pact with Oncolys BioPharma, a privately held Japanese biotech company, that will give it control of a promising new HIV treatment.

NEW YORK and TOKYO — Bristol-Myers Squibb has signed a definitive licensing pact with Oncolys BioPharma, a privately held Japanese biotech company, that will give it control of a promising new HIV treatment.